PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-26.20%
Both yoy net incomes decline, with AGEN at -33.83%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
3.65%
D&A growth well above AGEN's 5.45%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
-4.67%
Negative yoy SBC while AGEN is 20.19%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-515.11%
Negative yoy working capital usage while AGEN is 278.67%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.40%
Some yoy usage while AGEN is negative at -121.13%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-12704.62%
Negative yoy while AGEN is 111.17%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-57.07%
Negative yoy CFO while AGEN is 19.74%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-196.22%
Both yoy lines negative, with AGEN at -20.46%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-196.22%
Both yoy lines negative, with AGEN at -20.32%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We slightly raise equity while AGEN is negative at -40.87%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.